Laura Villa
Plus aucun poste en cours
Profil
Laura Villa worked as a Director of Investor Relations and Communication at AGC Biologics SpA, a Director of Investor Relations at Sorin SpA, a Media Relations Contact at CTI BioPharma Corp., and an Investor Relations Specialist at DiaSorin SpA.
She also obtained an undergraduate degree from the University of Bocconi.
Anciens postes connus de Laura Villa
| Sociétés | Poste | Fin |
|---|---|---|
| SORIN SPA | Investor Relations Contact | - |
| CTI BIOPHARMA CORP. | Public Communications Contact | - |
| MOLMED S.P.A. | Investor Relations Contact | - |
| DIASORIN S.P.A. | Public Communications Contact | - |
Formation de Laura Villa
| University of Bocconi | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DIASORIN S.P.A. | Health Technology |
| Entreprise privées | 3 |
|---|---|
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
AGC Biologics SpA
 AGC Biologics SpA Pharmaceuticals: MajorHealth Technology AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy. | Health Technology |
Sorin SpA
 Sorin SpA Medical SpecialtiesHealth Technology Sorin SpA engages in the research, development, and manufacture of technology products for the treatment of cardiovascular diseases. It operates through the Cardiac Surgery and Cardiac Rhythm business segments. The Cardiac Surgery segment involves in the production and marketing of single-use biomedical devices, systems used to ensure out-of-body circulation in cardiac surgical procedures, and implantable prosthetics to replace or repair heart valves. The Cardiac Rhythm segment deals with the production and marketing of implantable devices and monitoring equipment and accessories to protect against heartbeat disorders. The company was founded in 1956 and is headquartered in Milan, Italy. | Health Technology |
